1
|
Cho EY, Ryu JY, Lee HAR, Hong SH, Park HS, Hong KS, Park SG, Kim HP, Yoon TJ. Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes. J Nanobiotechnology 2019; 17:19. [PMID: 30696428 PMCID: PMC6350399 DOI: 10.1186/s12951-019-0452-8] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2018] [Accepted: 01/10/2019] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Protein-based Cas9 in vivo gene editing therapeutics have practical limitations owing to their instability and low efficacy. To overcome these obstacles and improve stability, we designed a nanocarrier primarily consisting of lecithin that can efficiently target liver disease and encapsulate complexes of Cas9 with a single-stranded guide RNA (sgRNA) ribonucleoprotein (Cas9-RNP) through polymer fusion self-assembly. RESULTS In this study, we optimized an sgRNA sequence specifically for dipeptidyl peptidase-4 gene (DPP-4) to modulate the function of glucagon-like peptide 1. We then injected our nanocarrier Cas9-RNP complexes directly into type 2 diabetes mellitus (T2DM) db/db mice, which disrupted the expression of DPP-4 gene in T2DM mice with remarkable efficacy. The decline in DPP-4 enzyme activity was also accompanied by normalized blood glucose levels, insulin response, and reduced liver and kidney damage. These outcomes were found to be similar to those of sitagliptin, the current chemical DPP-4 inhibition therapy drug which requires recurrent doses. CONCLUSIONS Our results demonstrate that a nano-liposomal carrier system with therapeutic Cas9-RNP has great potential as a platform to improve genomic editing therapies for human liver diseases.
Collapse
Affiliation(s)
- Eun Yi Cho
- College of Pharmacy, Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, 206 Worldcup-ro, Yeongtong-gu, Suwon, 16499 South Korea
- Moogene Medi Co. Ltd., Korea Bio Park, Daewangpangyo-ro 700, Seongnam, 13488 South Korea
| | - Jee-Yeon Ryu
- College of Pharmacy, Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, 206 Worldcup-ro, Yeongtong-gu, Suwon, 16499 South Korea
| | - Han A. Reum Lee
- College of Pharmacy, Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, 206 Worldcup-ro, Yeongtong-gu, Suwon, 16499 South Korea
| | - Shin Hee Hong
- College of Pharmacy, Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, 206 Worldcup-ro, Yeongtong-gu, Suwon, 16499 South Korea
| | - Hye Sun Park
- Bioimaging Research Team, Korea Basic Science Institute, Cheongju, 28119 South Korea
| | - Kwan Soo Hong
- Bioimaging Research Team, Korea Basic Science Institute, Cheongju, 28119 South Korea
| | - Sang-Gyu Park
- College of Pharmacy, Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, 206 Worldcup-ro, Yeongtong-gu, Suwon, 16499 South Korea
| | - Hong Pyo Kim
- College of Pharmacy, Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, 206 Worldcup-ro, Yeongtong-gu, Suwon, 16499 South Korea
| | - Tae-Jong Yoon
- College of Pharmacy, Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, 206 Worldcup-ro, Yeongtong-gu, Suwon, 16499 South Korea
- Moogene Medi Co. Ltd., Korea Bio Park, Daewangpangyo-ro 700, Seongnam, 13488 South Korea
| |
Collapse
|